How Cannabis Interacts With Chronic Lyme Inflammation

In this state, cannabinoids may function as exogenous ligands that support the body in restoring balance to a depleted physiological state.

Technical Mechanisms: How Cannabinoids Interact with Lyme Pathology

• Retrograde Signaling & Excitotoxicity: Cannabinoids travel backward across the synapse to bind with presynaptic CB1 receptors. This activity may inhibit the release of glutamate, the brain’s primary excitatory neurotransmitter, potentially helping to manage the excitotoxicity associated with neuroborreliosis.
• NF-κB Inhibition: By activating CB2 receptors, cannabinoids may interrupt the Nuclear Factor-kappa B (NF-κB) pathway, supporting the reduction of pro-inflammatory cytokines like IL-1β and TNF-α.
• FAAH Modulation: CBD acts as a competitive inhibitor of Fatty Acid Amide Hydrolase (FAAH). By blocking this enzyme, CBD may preserve levels of the body's internal molecule, anandamide, allowing it to remain active longer.
• Mitochondrial Regulation: Cannabinoids interact with MT-CB1 receptors located on mitochondrial membranes, which may help manage oxidative stress and support stable ATP production.
• COX-2 Inhibition: The acidic precursors CBDA and THCA naturally inhibit the cyclooxygenase-2 (COX-2) enzyme, which may lower systemic prostaglandin levels—offering anti-inflammatory support.

Mitigating Neuroborreliosis: CB1 Receptors and Glutamate

Lyme-related sensory overload and neuropathic pain are frequently driven by an excess of excitatory signals in the central nervous system. In a standard synapse, neurotransmitters move forward. Cannabinoids utilize retrograde signaling. The receiving neuron sends endocannabinoids (AEA and 2-AG) backward to the sending neuron’s CB1 receptors. This serves as a biological "stop" command, which may help mute the inflammatory firing that characterizes chronic neuro-Lyme.

Immune Vigilance: CB2 and the NF-κB Pathway

In PTLDS, the immune system often remains hyper-vigilant. CB2 receptors, which are found on leukocytes and microglia, act as a rheostat for this peripheral response. When a ligand like CBD or the terpene Beta-caryophyllene binds to the CB2 receptor, it may keep the NF-κB pathway—the master transcription factor for inflammation—in the "off" position. This is a potential mechanism for addressing the migratory joint pain and vasculitis that often impacts Lyme patients.

Targeted Enzyme Inhibition and the GPR55 Receptor

ECS modulation reaches into "orphan" receptors and enzyme chains.

FAAH Inhibition and GPR55 Antagonism

While CBD has low binding affinity for CB1/CB2, its efficacy is anchored in FAAH inhibition. By blocking the enzyme that degrades anandamide, CBD may bolster the body’s innate pain-management capacity.

CBD acts as an antagonist to GPR55, sometimes called the "third cannabinoid receptor." Over-activation of GPR55 is linked to bone reabsorption and joint degradation. By blocking this receptor, CBD may provide a protective barrier against the joint damage typical of chronic infection.

Shifting Microglial Phenotypes: From Defense to Repair

"Brain fog" is often the result of microglial activation. In chronic disease, these immune cells become trapped in the M1 phenotype, which is pro-inflammatory. M1 microglia release neurotoxins that can damage the blood-brain barrier.

Cannabinoids may facilitate a shift toward the M2 phenotype—the repair-oriented state. This transition is important, as it may allow the brain’s glymphatic system to flush out neurotoxic bacterial byproducts, moving the brain from a state of constant defense to one of clearance and recovery.

Mitochondrial Energy and MT-CB1

Chronic Lyme is associated with mitochondrial fatigue. Bacterial toxins may deplete cellular energy and crash ATP production. We now know that MT-CB1 receptors reside on the mitochondrial membranes. By modulating these receptors, cannabinoids may help the cell navigate oxidative stress, potentially mitigating the "energy burnout" that patients experience.

The Role of Raw Cannabinoids: CBDA and THCA

The acidic, raw forms of cannabinoids—CBDA and THCA—are often overlooked, yet they offer non-intoxicating tools:

• CBDA: A potent activator of 5-HT1A (serotonin) receptors, which may be effective for the nausea and autonomic dysfunction seen in complex Lyme cases.
• THCA: A neuroprotectant that modulates PPARγ (Peroxisome Proliferator-Activated Receptor gamma), which is involved in regulating glucose metabolism and inflammation.

A clinical approach that utilizes the full spectrum of cannabinoids—engaging CB1, CB2, GPR55, TRPV1, and MT-CB1 receptors—may provide support for the systemic, multi-faceted nature of Chronic Lyme Disease.

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Russo EB. (2004). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 25(1-2):31-9. PubMed

2. Cabral GA, Rogers TJ, Lichtman AH. (2015). Turning over a new leaf: cannabinoid and endocannabinoid modulation of immune function. J Neuroimmune Pharmacol. 10(2):193-203. PubMed

3. Mechoulam R, Parker LA. (2013). The endocannabinoid system and the brain. Annu Rev Psychol. 64:21-47. PubMed

4. Bénard G, Massa F, Bhaskaran MD, Marsicano G. (2012). Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci. 15(4):558-64. PubMed

5. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed